ODI Pharma Valuation
Is 6OD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6OD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6OD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6OD's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6OD?
Key metric: As 6OD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 6OD's PE Ratio? | |
|---|---|
| PE Ratio | 136.8x |
| Earnings | SEK 355.97k |
| Market Cap | SEK 48.70m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 37.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 6OD's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.2x | ||
93M1 MPH Health Care | 0.9x | -65.7% | €105.3m |
2FJ0 Pierrel | 29.9x | n/a | €92.8m |
CPMD CannaPharmaRX | 4.2x | n/a | US$2.0m |
KPRX Kiora Pharmaceuticals | 1.8x | -40.4% | US$9.9m |
6OD ODI Pharma | 136.8x | n/a | €48.7m |
Price-To-Earnings vs Peers: 6OD is expensive based on its Price-To-Earnings Ratio (136.8x) compared to the peer average (9.2x).
Price to Earnings Ratio vs Industry
How does 6OD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 6OD is expensive based on its Price-To-Earnings Ratio (136.8x) compared to the European Pharmaceuticals industry average (21.3x).
Price to Earnings Ratio vs Fair Ratio
What is 6OD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 136.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6OD's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.74
7D
1.9%
1Y
-7.4%
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%